<DOC>
	<DOCNO>NCT00125788</DOCNO>
	<brief_summary>The purpose research evaluate effect L-glutamine therapy sickle cell anemia sickle ß0-thalassemia . evaluate number occurrence sickle cell crisis .</brief_summary>
	<brief_title>L-Glutamine Therapy Sickle Cell Anemia Sickle ß0 Thalassemia</brief_title>
	<detailed_description>The primary purpose study evaluate effectiveness oral L-glutamine therapy sickle cell anemia sickle ß0-thalassemia . The secondary purpose assess effect L-glutamine pain ; energy appetite level ; narcotic usage ; height weight ; hospital emergency room visit sickle cell pain . Methodology : By site , patient randomize L-glutamine placebo 1:1 ratio 4-week screening period . Patients undergo 48 week treatment dose BID orally , dose calculate accord patient weight . Patient visit occur every 4 week . After 48 week treatment , dose tapered zero within 3 week . A final evaluation visit occur 2 week last dose .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>To eligible participate study , patient must meet follow inclusion criterion : Patient least five year age . Patient diagnose sickle cell anemia sickle ß0thalassemia ( document hemoglobin electrophoresis ) . Patient least two episode painful crisis within 12 month screen visit . If patient treat antisickling agent within three month screen visit , therapy must continuous least three month intent continue next 14 month . Patient patient 's legally authorize representative give write informed consent . If patient female childbearing potential , agree practice recognize form birth control course study . If patient meet follow criterion , patient must enrol : Patient significant medical condition require hospitalization ( sickle painful crisis ) within two month screen visit . Patient diabetes mellitus untreated fast blood sugar &gt; 115 mg/dL . Patient prothrombin time International Normalized Ratio ( INR ) &gt; 2.0 . Patient serum albumin &lt; 3.0 g/dl . Patient receive blood product within three week screen visit . Patient history uncontrolled liver disease renal insufficiency . Patient pregnant lactating . Patient treat experimental antisickling medication/treatment ( except hydroxyurea ) within 30 day screen visit . Patient treat experimental drug within 30 day screen visit . There factor would , judgment investigator , make difficult patient comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>sickle cell anemia</keyword>
	<keyword>L-glutamine</keyword>
	<keyword>Sickle Cell Anemia ( homozygous )</keyword>
	<keyword>Sickle ß0-Thalassemia</keyword>
</DOC>